ClinicalTrials.gg
Status unknownNCT04814641Updated Mar 24, 2021

Hypophosphatemia and Bronchiolitis

An observational study in Hypophosphatemia and Bronchiolitis, sponsored by Hospices Civils de Lyon. Status unknown at 1 site in France. Open to participants aged 7 Days to 3 Months. Per ClinicalTrials.gov, last updated 2021-03-24.

Sponsored by Hospices Civils de Lyon · Observational

The sponsor has not verified this record recently (last verified Mar 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
400
Ages
7 Days to 3 Months
Sex
All
01

Study summary

Bronchiolitis is a major public health problem and the leading cause of paediatric intensive care unit admission in infants. Hypophosphatemia is common in adult intensive care units and was associated with an increase of the duration of mechanical ventilation and the length of stay. Our hypothesis is that hypophosphatemia is common in bronchiolitis and could be a marker of severity.

02

Conditions studied

  • Hypophosphatemia
  • Bronchiolitis

Keywords

  • Hypophosphatemia
  • Bronchiolitis
  • Paediatric Intensive Care Unit
  • Risk Factor
03

In context

Hypophosphatemia

53 studies on the registry are indexed under Hypophosphatemia; 16 are open to participants now.

This study's planned enrollment of 400 is above the median of 105 across 26 observational studies indexed under Hypophosphatemia.

Browse Hypophosphatemia studies →

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,866 studies on the registry; 448 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Days to 3 Months
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Infant less than 3 months with severe bronchiolitis admitted in a pediatric intensive care unit

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 7 days and \< 3 months of life
  • Admission to the pediatric intensive care unit from 01/11/2016 to 31/03/2020
  • With a diagnosis of moderate to severe bronchiolitis according to HAS 2019 criteria

Exclusion criteria

Exclusion Criteria:

  • Renal Failure and tubulopathy
  • Previous disorder of phospho-calcium balance
  • Malignant pathology
  • Lenght of stay less than 24 hours
  • History of cardiac, aortic or hepatic surgery
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Infants with hypophosphatemia

    Infant less than 3 months with severe bronchiolitis admitted in a pediatric intensive care unit, with hypophosphatemia in the first 5th days

    Biological: hypophosphatemia occurrence in infants with severe bronchiolitis admitted in a pediatric intensive care unit

  • Infants without hypophosphatemia

    Infant less than 3 months with severe bronchiolitis admitted in a pediatric intensive care unit, without hypophosphatemia

    Biological: hypophosphatemia occurrence in infants with severe bronchiolitis admitted in a pediatric intensive care unit

Interventions

  • Biologicalhypophosphatemia occurrence in infants with severe bronchiolitis admitted in a pediatric intensive care unit

    Serum phosphorus level \< 1.55 mmol/L at any time between admission and the 5th day.

06

What researchers measure

Primary outcomes

  1. hypophosphatemia occurrence in severe bronchiolitis in infants admitted in a pediatric intensive care unit

    A serum phosphorus level\< 1.55mmol/L defines the hypophosphatemia.

    Time frame: At any time in the first 5th days after Pediatric intensive care admission

07

Study locations

1 of 1 sites recruiting
  • Hopital Femme Mere Enfant - Groupement Hospitalier Est
    Bron, 69677, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2021 (actual). Primary completion is estimated for May 2021, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2021
First posted
Mar 24, 2021
StartActual
Mar 21, 2021
Primary completionEst.
May 2021
CompletionEst.
Jun 2021
Last update
Mar 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04814641
Responsible party
Sponsor
First posted
Mar 24, 2021
Start date
Mar 21, 2021
Primary completion
May 2021 (estimated)
Completion
Jun 2021 (estimated)
Last update
Mar 24, 2021

Study contacts

Florent Baudin, Dr
Contact
florent.baudin@chu-lyon.fr
4 72 12 97 35 ext. +33

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion